Brief: Trinity Biotech Acquires Metabolomics Diagnostics
24/09/2024 21:11
Sept 24 (Reuters) - Trinity Biotech PLC TRIB.O :
* TRINITY BIOTECH ANNOUNCES ACQUISITION OF METABOLOMICS
DIAGNOSTICS TO GROW PRESENCE IN MATERNAL HEALTH MARKET
* TRINITY BIOTECH PLC - DEAL VALUES METABOLOMICS DIAGNOSTICS
AT
$1.3 MILLION
* TRINITY BIOTECH PLC - PREPSIA TEST TO BE COMMERCIALIZED IN
U.S.
IN 2025
* TRINITY BIOTECH PLC - FIRST REVENUES FROM PREECLAMPSIA
TESTING
EXPECTED IN 2025
Source text for Eikon: ID:nGNXbRbk06
Further company coverage: TRIB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trinity Biotech
See all newsNASDAQ RESUMED AT 12:18 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:13 PM
Brief: Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Brief: Trinity Biotech’S Trinovium Subsidiary Agrees To Collaborate With Echelon Data Centres To Develop Advanced Liquid Cooling Solutions For Ai Infrastructure
NASDAQ RESUMED AT 09:00 AM